Tricyclic Polypeptide Drug Conjugates for Nectin-4 Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic drugs targeting Nectin-4, a tumor-associated target, have limited applications and efficacy for various cancers, necessitating the development of more effective compounds.
Innovation Solution
Development of tricyclic polypeptide conjugated drugs, represented by specific formulas, with varying alkyl and amino acid substitutions, that exhibit strong binding to Nectin-4 and demonstrate anti-tumor activity in preclinical models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic drugs are used to target Nectin-4, then treatment is available for some cancers, but the efficacy is limited and applications are restricted
Solution Approach 1:
The patent modifies the chemical structure parameters of conventional chemotherapeutic drugs by introducing a tricyclic polypeptide conjugate system with specific amino acid sequences and structural features (formulas I and II with varying R1, R2, and n parameters). This structural parameter change enhances binding affinity to Nectin-4 while maintaining cytotoxic activity, thereby improving both efficacy and applicability across different cancer types including breast, lung, and gastric cancers
Solution Approach 2:
The invention creates a composite structure by conjugating tricyclic polypeptide molecules with chemotherapeutic drug molecules. The polypeptide portion (with specific sequences containing amino acids like Cys, hCys, βCys, or Pen) serves as a targeting moiety that binds to Nectin-4, while the attached chemotherapeutic agent provides the cytotoxic effect. This composite design enables selective delivery of the drug to Nectin-4 expressing tumor cells, improving both efficacy and versatility across multiple cancer indications
2Reliability
If tricyclic polypeptide conjugated drugs are developed with complex structures, then binding affinity to Nectin-4 improves, but synthesis and manufacturing complexity increases
Solution Approach 1:
The patent divides the conjugate molecule into distinct functional segments: a tricyclic polypeptide portion with specific amino acid sequences (formulas I and II) and a chemotherapeutic drug portion. This segmentation allows for modular synthesis where the polypeptide can be synthesized separately using solid-phase peptide synthesis methods, then conjugated to the chemotherapeutic agent through established chemical coupling techniques. The segmented approach simplifies the overall manufacturing process compared to synthesizing the entire conjugate as a single complex molecule
Solution Approach 2:
The patent employs linker chemistry as an intermediary approach to connect the polypeptide and chemotherapeutic drug components. The conjugation utilizes standard chemical linkers and coupling reagents (such as EDC/NHS chemistry or thiol-maleimide reactions) that are well-established in pharmaceutical manufacturing. This intermediary connection strategy enables the use of existing, scalable synthesis methodologies for both the polypeptide and drug components, facilitating easier manufacturing while maintaining the required binding affinity through optimized linker design
Data Source
AI summary
A tricyclic polypeptide conjugated drug and the use thereof are provided. Specifically provided are a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the compound or the pharmaceutically acceptable salt thereof is further provided. The compound or the pharmaceutically acceptable salt thereof and the pharmaceutical composition can be used in the preparation of a drug for treating Nectin-4 overexpressed solid tumors.